MannKind Corporation - ROE
MNKD
Price:
$3.94
Market Cap:
$1.22B
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, ...[Read more]
Industry
Biotechnology
IPO Date
2004-07-28
Stock Exchange
NASDAQ
Ticker
MNKD
PE Ratio
[-56.29]
ROE
[45.59%]
Current Ratio
[1.87]
Dividend Yield
[0%]
Enterprise Value
[1.60B]
Dividend History
The ROE as of June 2026 (TTM) for MannKind Corporation (MNKD) is 45.59%
According to MannKind Corporation’s latest financial reports and current stock price. The company's current ROE is 45.59%. This represents a change of 353.70% compared to the average of 10.05% of the last 4 quarters.
MannKind Corporation (MNKD) Historical ROE (quarterly & annually)
How has MNKD ROE performed in the past?
The mean historical ROE of MannKind Corporation over the last ten years is 12.67%. The current 45.59% ROE has changed 259.74% with respect to the historical average. Over the past ten years (40 quarters), MNKD's ROE was at its highest in in the December 2025 quarter at 31.26%. The ROE was at its lowest in in the September 2016 quarter at -53.01%.
Average
12.67%
Median
29.48%
Minimum
-68.45%
Maximum
54.64%
MannKind Corporation (MNKD) ROE by Quarter and Year
Discovering the peaks and valleys of MannKind Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 21.84%
Maximum Annual ROE = 54.64%
Minimum Annual Increase = -821.78%
Minimum Annual ROE = -68.45%
| Year | ROE | Change |
|---|---|---|
| 2025 | -11.49% | -67.17% |
| 2024 | -35.00% | -821.78% |
| 2023 | 4.85% | -86.10% |
| 2022 | 34.88% | -9.76% |
| 2021 | 38.66% | 21.84% |
| 2020 | 31.73% | 16.46% |
| 2019 | 27.24% | -45.16% |
| 2018 | 49.68% | -9.09% |
| 2017 | 54.64% | -179.83% |
| 2016 | -68.45% | -165.08% |
MannKind Corporation (MNKD) Average ROE
How has MNKD ROE performed in the past?
The current ROE of MannKind Corporation (MNKD) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-13.88%
5-year avg
6.38%
10-year avg
12.67%
MannKind Corporation (MNKD) ROE vs. Peers
How is MNKD’s ROE compared to its peers?
MannKind Corporation’s ROE is less than Aurinia Pharmaceuticals Inc. (64.48%), less than Harmony Biosciences Holdings, Inc. (17.19%), greater than Celldex Therapeutics, Inc. (-50.72%), greater than Vera Therapeutics, Inc. (-74.86%), greater than Janux Therapeutics, Inc. (-11.85%), greater than AbCellera Biologics Inc. (-14.86%), greater than Nuvation Bio Inc. (-44.10%), greater than Immunocore Holdings plc (-4.83%), greater than Biohaven Ltd. (-866.46%), greater than Sionna Therapeutics, Inc. (-27.31%),
| Company | ROE | Market cap |
|---|---|---|
| 64.48% | $2.12B | |
| 17.19% | $1.93B | |
| -50.72% | $2.16B | |
| -74.86% | $2.52B | |
| -11.85% | $867.20M | |
| -14.86% | $1.69B | |
| -44.10% | $1.93B | |
| -4.83% | $1.45B | |
| -866.46% | $1.44B | |
| -27.31% | $1.68B |
Build a custom stock screener for MannKind Corporation (MNKD) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MannKind Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
MannKind Corporation (MNKD) and other stocks custom spreadsheet templates
The easiest way to analyze a company like MannKind Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is MannKind Corporation's ROE?
How is the ROE calculated for MannKind Corporation (MNKD)?
What is the highest ROE for MannKind Corporation (MNKD)?
What is the 3-year average ROE for MannKind Corporation (MNKD)?
What is the 5-year average ROE for MannKind Corporation (MNKD)?
How does the current ROE for MannKind Corporation (MNKD) compare to its historical average?